deprexis® flexibly integrates into your treatment plan and is designed to help you integrate psychotherapy into your care concept, without demanding more staff training or time.
deprexis® offers a clinically validated digital treatment to support patients with depressive symptoms, allowing you to increase your patient reach, cost effectiveness and revenue.
Using CBT and other psychotherapeutic principles, deprexis® teaches patients self-management, so you can focus on deepening your counseling and therapy during in-person sessions.
deprexis®’ fully automated, AI-powered technology can be easily integrated into any existing care plan. deprexis® can also be accessed through all devices with internet capabilities, allowing patients to integrate methods that help them manage their depression anytime, anywhere, in the available language most convenient to them.
RCTs demonstrate deprexis®’ effectiveness, safety and suitability.
Nine independent studies conducted with deprexis® have demonstrated its effectiveness and have confirmed the increase in benefits when deprexis® is added to existing care plans.
Depression is especially prevalent in patients with severe medical conditions and disorders. deprexis® has been shown to effectively treat depression as a comorbidity of epilepsy, multiple sclerosis and gambling disorder.
A study of 3,805 participants demonstrated using deprexis® significantly reduces the cost of treating depression for health insurers, while simultaneously reducing depressive symptoms and increasing quality of life in patients.
Gräfe et al. (2020)
Multiple meta-analyses and systematic reviews have confirmed the scientific evidence gathered in 13 RCTs that deprexis® is an effective treatment for depression.
USA: University of Texas, Austin; Cedars Sinai Medical Center Los Angeles; University of Massachusetts Medical School
SWEDEN: The Karolinska Institute; Linkoping University
GERMANY: Universitätsklinikum Hamburg-Eppendorf (UKE); Charite Universitätsmedizin Berlin; Universität Trier; Universität Tübingen
UK: University of Cambridge; Kings College London; City University, London
FUNDING PARTNERS: the U.S. department of veteran affairs, the U.S. national multiple sclerosis society, the European Union, the European Commission, the German ministry of health, and the Brain and Behavior Research Foundation, the German Association of Psychotherapists (DPTV), major German health insurance companies and several other research centers, universities and hospitals across Europe, the U.S. and other regions.